WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
State Supreme Court and Republican congressional primary elections top Georgia ballots
Kylian Mbappe informs PSG he will not trigger contract extension
Enterprises bullish on supply chain expo
Surfers converge on Hainan for championships
French Olympic fencer Thibus says she has been cleared of any wrongdoing after abnormal doping test
Zhang primed for shot at history
Messi not planning to play at 2026 World Cup
Turkish Airlines resumes flights to Afghanistan nearly 3 years after the Taliban captured Kabul
NPPA says it approves 105 home